Stocktoria
Xeris Biopharma Holdings, Inc. XERS
Xeris Biopharma Holdings, Inc. (XERS) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $291.8M at a 0.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.341 |
| Retained earnings / assets | -1.75 |
| EBIT / assets | 0.065 |
| Equity / liabilities | 0.037 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| XERS | Xeris Biopharma Holdings, Inc. | 7/9 | -2.99 | — | +43.7% |
| RIGL | RIGEL PHARMACEUTICALS INC | 5/9 | 0.31 | 2 | +64.1% |
| IRWD | IRONWOOD PHARMACEUTICALS INC | 4/9 | -11.97 | 28.3 | -15.7% |
| EOLS | Evolus, Inc. | 2/9 | -8.65 | — | +11.6% |
| AUPH | Aurinia Pharmaceuticals Inc. | 5/9 | 5.18 | 7.7 | +20.4% |
| HROW | HARROW, INC. | 6/9 | 1.29 | — | +36.4% |
| CRMD | CorMedix Inc. | 5/9 | 3.07 | 3.8 | +617% |
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
FAQ
Is XERS financially healthy?
Xeris Biopharma Holdings, Inc.'s Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does XERS pay a dividend?
No, Xeris Biopharma Holdings, Inc. does not currently pay a dividend.
How profitable is XERS?
In FY2025, Xeris Biopharma Holdings, Inc. had a net margin of 0.2% and a return on equity of 4.0%.
What is the analyst price target for XERS?
The average Wall-Street price target for Xeris Biopharma Holdings, Inc. is $11.29, about 32.9% above the recent price, from 7 analysts (consensus: strong buy).
Is XERS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Xeris Biopharma Holdings, Inc.: a Piotroski F-score of 7/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.